Oncotarget

Dr. Sridhar Mani from Medicine and Genetics of The Albert Einstein College of Medicine, Bronx, NY, details his editorial published by Oncotarget in Volume 11, Issue 19, entitled, “Microbial metabolite mimicry: one step closer to drug discovery.” DOI - https://doi.org/10.18632/oncotarget.27591 Correspondence to - Sridhar Mani - sridhar.mani@einsteinmed.org Sign up for free Altmetric alerts about th...

Head and neck cancer is a group of various tumors located in the oral cavity, oropharynx, larynx, and hypopharynx. Head and neck cell squamous-cell carcinomas (HNSCC) often result from tobacco use or human papillomavirus (HPV+) infection. In locally advanced HNSCC, the current therapies used are combined surgery, radiotherapy and chemotherapy. Despite the use of traditional treatments, up to 50% o...

BUFFALO, NY, January 6, 2022 – Since its inception in 2010, Oncotarget has operated as a traditional-style journal that publishes online page numbered issues of peer-reviewed papers. Final paginated issues were then released in their permanent form to Pubmed. As of 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in thei...

Statistics from the American Cancer Society indicate that endometrial cancer (EC) is on the rise among women in the United States. While it more commonly affects older women, researchers are finding that EC is the only gynecological cancer today increasing in incidence and mortality among younger women. Not to be confused with the benign condition of endometriosis, EC tumors are highly heterogeneo...

Oncotarget published "Host targeted antiviral (HTA): functional inhibitor compounds of scaffold protein RACK1 inhibit herpes simplex virus proliferation" which reported that due to the small number of molecular targets in viruses and the rapid evolution of viral genes, it is very challenging to develop specific antiviral drugs. In addition, HIV-1 and Herpes Simplex virus are known to use IRES as w...

The cover for issue 29 of Oncotarget features Figure 2, "Categorisation of samples analysed," from Laes, et al. - OncoDNA treatment recommendation followed in 60% of cases - 93% of treatment decisions were made based on a holistic approach combining next generation sequencing (NGS) and multiple biomarker analysis provided by OncoDNA - 27% of late-stage patients treated with OncoDNA-recommended the...

Oncotarget published "Genomic and neoantigen evolution from primary tumor to first metastases in head and neck squamous cell carcinoma" which reported that prior work has characterized changes in the mutation burden between primary and recurrent tumors; however, little work has characterized the changes in neoantigen evolution. These authors characterized genomic and neoantigen changes between 23...

Lung cancer continues to be the leading cause of cancer deaths world-wide. Variations in the stage of diagnosis, subtypes and types of mutated genes provide a challenge for researchers who are developing targeted treatments to help rid patients of lung cancer. To this end, many researchers are interested in employing cancer-testis antigens (CTAs), which are minimally expressed in normal tissues, b...

View the latest oncology-focused research published in this week’s issue of Oncotarget, Volume 12, Issue 25. https://www.oncotarget.com/archive/v12/i25/ Research Paper (Cover) - “Molecular characterization of Kita-Kyushu lung cancer antigen (KK-LC-1) expressing carcinomas” https://doi.org/10.18632/oncotarget.28132 Research Paper - “Radiomics in predicting recurrence for patients with locally advan...

Oncotarget Volume 11 Issue 15 reported that several zebrafish T-ALL models have been reported, but until recently, robust D. rerio B-ALL models were not described. Here, the Research Team has shown new B-ALL findings in one of these models, fish expressing transgenic human MYC. They describe B-ALL incidence in a large cohort of hMYC fish, and show B-ALL in two new lines where T-ALL does not interf...

Oncotarget published "CrkL is required for donor T cell migration to GvHD target organs" which reported that the success of cancer therapies based on allogeneic hematopoietic stem cell transplant relies on the ability to separate graft-versus-host disease from graft-versus-tumor responses. In vitro, CrkL-deficient T cells fail to polymerize actin in response to the integrin ligand ICAM-1, resultin...

Volume 11, Number 21 of Oncotarget reported that eligible patients with stable or responding mPDA after 6 months on chemotherapy were randomized 1:1 to metformin alone or with rapamycin, stratified by prior treatment with FOLFIRINOX. Metformin +/ rapamycin maintenance for mPDA was well-tolerated and several patients achieved stable disease associated with exceptionally long survival. Dr. Dung T. L...

Oncotarget published "Innovating and expanding weight loss strategies for breast cancer survivors" which reported that overweight and obesity are prevalent in over two thirds of the general population in the United States and are associated with an increased risk of malignancies, including breast cancer. This weight gain may increase risk of recurrence by 40–50%, and breast cancer-related mortalit...

Oncotarget published "Reversing oncogenic transformation with iron chelation" which reported that cancer cells accumulate iron to supplement their aberrant growth and metabolism. Depleting cells of iron by iron chelators has been shown to be selectively cytotoxic to cancer cells in vitro and in vivo. A plethora of studies have shown iron chelators can reverse some of the major hallmarks and enabli...

The cover for issue 36 of Oncotarget features Figure 7, "Knockdown of APOBEC3B is associated with a lower tumor growth in an adrenocortical carcinoma xenograft mouse model," by Gara, et al. which reported that the role of APOBEC3B in adrenocortical carcinoma and the mechanisms through which its expression is regulated in cancer are not fully understood. Here, the authors report that APOBEC3B is ov...

According to the Centers for Disease Control and Prevention (CDC), colorectal cancer is the second leading cause of cancer death in the United States. Researchers have observed elevated levels of the macrophage inflammatory protein CCL20 in colorectal cancer. Interactions between CCL20 and its receptor, CCR6, promote colorectal cancer through effects on neoplastic epithelial cells and modulation o...

Listen to short summaries of the latest oncology-focused research published in this week’s issue of Oncotarget, Volume 12, Issue 24. https://www.oncotarget.com/archive/v12/i24/ Research Paper (Cover) - “CCL20 induces colorectal cancer neoplastic epithelial cell proliferation, migration, and further CCL20 production through autocrine HGF-c-Met and MSP-MSPR signaling pathways” https://doi.org/10.186...

Oxybenzone (benzophenone-3; BP-3) is a toxic endocrine-disrupting chemical (EDC). Alarmingly, this chemical has been identified as a common ingredient in some brands of sunscreen. Oxybenzone can often be found in humans, household dust, fish and, due to its widespread human use, the water environment—causing harm to coral reefs and other murine life. Previous studies have shown that environmental...

Oncotarget Volume 11, Issue 8 reported Independent validation cohorts of 599 cases of early-stage CRC and 91 cases of late-stage CRC were examined. Multivariate and univariate survival analyses revealed that high expression of P4HA1 protein was an independent poor prognostic marker for patients with early-stage CRC, especially of the microsatellite stable subtype. Dr. Michael H. Roehrl from the De...

Here the research team tested a safe and well-established microbe-based immune adjuvant to restore immune homeostasis and counteract inflammation-associated obesity in animal models. Taken together, they concluded that oral vaccination with cholera toxin B helps stimulate health-protective immune responses that counteract age-associated obesity. Dr. Susan E. Erdman from the Division of Comparative...

The identification of an actionable gene mutation or translocation in patients with cancer can give researchers a target for new drug therapies. One such mutation, found in some patients with non-small cell lung cancer (NSCLC), is anaplastic lymphoma kinase (ALK) gene rearrangement. However, the exact population of patients that present with ALK rearrangement has not been fully characterized. Iden...

Listen to the latest oncology-focused research published in this week’s issue of Oncotarget, Volume 12, Issue 23. https://www.oncotarget.com/archive/v12/i23/ Research Paper (Cover) - “Anaplastic lymphoma kinase rearrangement prevalence in patients with advanced non-small cell lung cancer in the United States – retrospective real world data” https://doi.org/10.18632/oncotarget.28114 News - “Excitem...

Over the past few decades, numerous studies have emerged using the promising strategy of bacteria as vehicles to deliver drugs or genes in tumor‐targeted therapies. Researchers say that bacterial cancer therapy may be able to overcome some of the limitations that conventional cancer therapy is stunted by, including the development of drug resistance. In a 2020 study, researchers—from Yale Universi...

Oncotarget published "Benzophenone-3 promotion of mammary tumorigenesis is diet-dependent" which reported that Benzophenone-3 is a putative endocrine disrupting chemical and common ingredient in sunscreens. Although benzophenone-3 seemed protective on low-fat diet, spindle cell tumors arising in these mice showed increased proliferation and decreased apoptosis. This points to a need for further st...

The most common type of breast cancer in the United States is HR+/HER2− breast cancer. Patients with HR+/HER2− breast cancer often face the threat of distant recurrence—long after the completion of their treatment. Previous studies have found that high levels of tumor infiltrating lymphocytes (TILs) were associated with improved outcomes and recurrence-free survival in patients with HR+/HER2− brea...